Ad
MTSR Stock - Metsera Stock Trading
About | Metsera Inc. (NASDAQ:MTSR)
Quote | Metsera Inc. (NASDAQ:MTSR)
| Last: | $29.08 |
|---|---|
| Change Percent: | 4.94% |
| Open: | $29.5 |
| Close: | $27.71 |
| High: | $30.67 |
| Low: | $28.33 |
| Volume: | 571,375 |
| Last Trade Date Time: | 06/20/2025 11:50:23 am |
News | Metsera Inc. (NASDAQ:MTSR)
-
2025-06-14 08:46:43 ET More on Eli Lilly Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript Eli Lilly: If You Don't Buy On Weight Loss Promise Now, You Probably Never Will Targeting The NaV1.8 Pathway In Pain Man...
-
2025-06-12 10:03:30 ET ... Read the full article on Seeking Alpha For further details see: Promising Results Of Amylin Analogs In Obesity: Metsera Case Review
Message Board Posts | Metsera Inc. (NASDAQ:MTSR)
| Subject | By | Source | When |
|---|---|---|---|
| No posts yet. | |||
News, Short Squeeze, Breakout and More Instantly...
Metsera Inc. Company Name:
MTSR Stock Symbol:
NASDAQ Market:
4.94% G/L:
$29.08 Last:
571,375 Volume:
$29.50 Open:
$27.71 Close:
Metsera Inc. Website:
Ad
-
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Ch...
-
Metsera Inc. (MTSR) is expected to report for Q1 2025
-
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chi...